Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Full Approval Sought for Carfilzomib in Multiple Myeloma

January 29th 2015

A supplemental New Drug Application has been submitted to the FDA for the full regulatory approval of carfilzomib as a treatment for patients with relapsed multiple myeloma.

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

January 20th 2015

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Pomalidomide Shows Benefits in Trials Testing New Combinations

January 20th 2015

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Multiple Myeloma Advances: Noted Hematologist Envisions Big Changes in Treatment Paradigms

January 20th 2015

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

Monoclonal Antibodies in Multiple Myeloma

January 12th 2015

Ixazomib and Elotuzumab in Multiple Myeloma

January 12th 2015

Pomalidomide and HDAC Inhibitors in Multiple Myeloma

January 12th 2015

Carfilzomib Combination in Relapsed Multiple Myeloma

January 12th 2015

Treatment of Elderly Patients With Multiple Myeloma

January 12th 2015

Transplant and Maintenance Therapy in Multiple Myeloma

January 12th 2015

Multiple Myeloma Treatment Regimens

January 12th 2015

Gene Expression Profiling in Multiple Myeloma

January 12th 2015

Introduction: Redefining Symptomatic Multiple Myeloma

January 12th 2015

Dr. Morgan on the Future of Myeloma Treatment

January 2nd 2015

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

December 29th 2014

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

December 8th 2014

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma

December 8th 2014

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.